EuroBiotech: More Articles of Note


> Eduardo Bravo left Nordic Nanovector to “pursue other career opportunities.” Bravo took over as CEO in 2018, shortly after leading TiGenix to a takeover by Takeda. Lars Nieba will serve as interim CEO of Nordic Nanovector. Statement  

> Advanced BioDesign raised €9 million ($10 million) to support its efforts to start a phase 1 trial in acute myeloid leukemia patients early next year. The French biotech is developing a suicide inhibitor of certain aldehyde dehydrogenases. Release  

> A phase 2 trial of IO Biotech’s IO102 and Keytruda cleared an interim futility analysis. IO Biotech said the combination had to achieve a response rate “substantially higher than the historical experience with Keytruda monotherapy in this population” to pass the futility analysis. Statement 

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

> ReNeuron reported long-term data from its phase 1/2a stem cell therapy trial. The update shows the improvements in visual acuity seen early in the trial continued out to 12 months. Release 

> Adrenomed posted top-line phase 2 data on adrecizumab in septic shock. The trial met its primary endpoint. Statement 

> The FDA scheduled an advisory committee meeting to discuss DBV Technologies’ Viaskin Peanut for May. DBV expects to learn whether the FDA will approve the product by early August. Release 

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.